Retatrutide 40mg Research Pen

40mg Retatrutide research pen

This 40mg pen is supplied for laboratory and in-vitro research only. The label states a total of 40mg retatrutide in the complete pen. That figure describes total labelled contents — it is not a personal dose, weekly schedule, or treatment recommendation.

About retatrutide (research context)

Retatrutide (also studied as LY3437943) is an investigational peptide researched for its activity at three metabolic receptor pathways: GIP, GLP-1, and glucagon. That triple-receptor profile is why some catalogues refer to related naming such as “GLP-3”. “GLP-3” here is a product naming convention; it does not identify a separate GLP-3 receptor.

How researchers describe the pathways

• GLP-1 pathway — studied in relation to glucose-dependent insulin signalling, appetite signalling, and gastric emptying.
• GIP pathway — also studied for glucose-dependent insulin signalling.
• Glucagon pathway — studied in relation to glucose regulation and energy metabolism.

Researchers examine how activating these pathways together affects metabolic responses, safety signals, and tolerability under controlled study conditions.

How this differs from related research compounds

• Semaglutide — typically studied at GLP-1 receptors.
• Tirzepatide — typically studied at GIP and GLP-1 receptors.
• Retatrutide — studied at GIP, GLP-1, and glucagon receptors.

Receptor count alone does not prove greater effectiveness or better safety. Meaningful comparison needs suitable experimental or clinical evidence, study populations, regimens, duration, outcomes, and adverse-effect data.

What the 40mg label means

The 40mg amount is the stated total quantity in the pen. It does not establish a recommended individual dose, a standard weekly amount, an approved treatment schedule, or a clinically validated 40mg regimen. Total pen contents and doses used in published trials describe different quantities — keep that distinction clear when reviewing research literature.

Published research note

Published Phase 2 obesity research has evaluated once-weekly investigational regimens over extended study periods in controlled conditions. Those findings relate to the trial medicine, participants, and protocol used in that research. They do not establish the safety or effectiveness of independently marketed research pens, and they do not create a link to any pharmaceutical company’s clinical-trial supply.

Quality, documentation, and storage

Review batch documentation before laboratory use, including identity, labelled quantity, and analytical results where available. Follow supplier guidance for storage and handling. This product is for qualified laboratory research only — not for human consumption, veterinary use, or diagnostic use.